Concepedia

Marion Wiesmann

MW

25

Publications

5.2K

Citations

21

H-Index

2001

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Novartis (China)

Harvard University

Marion Wiesmann is an author at Novartis (Switzerland) specializing in medicine, drug discovery, and tumor biology.

Top concepts

Publications per year

2001–2021

25

Publications

25

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Hui Gao, Joshua M. Korn, Stéphane Ferretti et al. · Nature Medicine · 2015 · 1.4K citations

, , +10

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

, , +26

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 462 citations

, , +18

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

Sadhna Vora, Dejan Juric, Nayoon Kim et al. · Cancer Cell · 2014 · 428 citations · Full text

, , +10

Elevated expression of <i>axin2</i> and <i>hnkd</i> mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors

Dong Yan, Marion Wiesmann, Michael Rohan et al. · Proceedings of the National Academy of Sciences · 2001 · 366 citations · Full text

Rows per page

1–5 of 25